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At the request of the U.S. Environmental
Protection Agency (U.S. EPA), the National
Toxicology Program (NTP)/National
Institute of Environmental Health Sciences
(NIEHS) organized and conducted an inde-
pendent and open peer review to evaluate
the scientiﬁc evidence on reported low-dose
effects and dose–response relationships for
endocrine-disrupting chemicals in mam-
malian species that pertain to assessments of
effects on human health. The peer review
took place in Research Triangle Park, North
Carolina, USA, on 10–12 October 2000. 
The purpose of this meeting was to estab-
lish a sound scientiﬁc foundation upon which
the U.S. EPA could determine what aspects,
if any, of its standard guidelines for reproduc-
tive and developmental toxicity testing need
to be modiﬁed to detect and characterize low-
dose effects of endocrine disruptors. Results
from this review may also influence how
other national and international agencies
select doses, end points, animal models, and
testing regimens for reproductive and devel-
opmental toxicity studies of endocrine-active
agents. In particular, the NTP is interested
in evaluating the molecular and physiologic
basis of dose–response relationships for
reproductive toxicants. For this peer review,
“low-dose effects” referred to biologic
changes that occur in the range of human
exposures or at doses lower than those typi-
cally used in the standard testing paradigm
of the U.S. EPA for evaluating reproductive
and developmental toxicity. The current rec-
ommended methods of the U.S. EPA are
described in “Health Effects Test Guidelines
OPPTS 870.3800 Reproduction and
Fertility Effects” (1). This review focused on
biologic change rather than on adverse effect
because, in many cases, the long-term health
consequences of altered endocrine function
during development have not been fully
characterized. 
The peer-review panel (the panel)
included individuals from academia, govern-
ment, and industry with expertise in recep-
tor/molecular biology, experimental and
clinical endocrinology, reproductive and
developmental toxicology, statistics, and
mathematical modeling. The panel was
divided into five subpanels: Bisphenol A;
Other Environmental Estrogens and
Estradiol; Androgens and Antiandrogens;
Biological Factors and Study Design; and
Statistics and Dose–Response Modeling. 
This peer review used a unique and
novel approach to evaluate the validity of
this very important and controversial envi-
ronmental health issue. Fifteen principal
investigators of primary research groups
active in this ﬁeld were asked by the organiz-
ing committee to provide their individual
animal data on selected parameters for inde-
pendent statistical reanalysis by the statistics
subpanel prior to the meeting. Data were
willingly submitted from 49 of the 59
selected studies. In general, certain requested
data sets were not provided because the data
were not available in an electronic format as
specified by the statistics subpanel, or the
raw data were in the possession of collabora-
tors and could not be provided in the
requested time frame. Studies for which
requested data sets were not submitted by
principal investigators for independent
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At the request of the U.S. Environmental Protection Agency (U.S. EPA), the National Toxicology
Program organized an independent and open peer review to evaluate the scientific evidence on
low-dose effects and nonmonotonic dose–response relationships for endocrine-disrupting chemi-
cals in mammalian species. For this peer review, “low-dose effects” referred to biologic changes
that occur in the range of human exposures or at doses lower than those typically used in the
standard testing paradigm of the U.S. EPA for evaluating reproductive and developmental toxic-
ity. The demonstration that an effect is adverse was not required because in many cases the long-
term health consequences of altered endocrine function during development have not been fully
characterized. A unique aspect of this peer review was the willing submission of individual animal
data by principal investigators of primary research groups active in this ﬁeld and the independent
statistical reanalyses of selected parameters prior to the peer review meeting by a subpanel of sta-
tisticians. The expert peer-review panel (the panel) also considered mechanistic data that might
inﬂuence the plausibility of low-dose effects and identiﬁed study design issues or other biologic
factors that might account for differences in reported outcomes among studies. The panel found
that low-dose effects, as defined for this review, have been demonstrated in laboratory animals
exposed to certain endocrine-active agents. In some cases where low-dose effects have been
reported, the findings have not been replicated. The shape of the dose–response curves for
reported effects varied with the end point and dosing regimen and were low-dose linear, thresh-
old-appearing, or nonmonotonic. The ﬁndings of the panel indicate that the current testing para-
digm used for assessments of reproductive and developmental toxicity should be revisited to see
whether changes are needed regarding dose selection, animal-model selection, age when animals
are evaluated, and the end points being measured following exposure to endocrine-active agents.
Key words: androgen, antiandrogen, bisphenol A, developmental toxicity, endocrine disruptors,
estrogen, in utero exposure, low-dose effects, multigeneration study, neonatal exposure, reproduc-
tive toxicity. Environ Health Perspect 110:427–431 (2002). [Online 12 March 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p427-431melnick/abstract.html
Workshop Summaryreview by the statistics subpanel were used as
background information by the panel.
Besides submitting their raw data, principal
investigators were asked to provide for each
study responses to a list of 23 questions on
issues relevant to the evaluation of endocrine
low-dose studies. These questions addressed
animal source and speciﬁcation, animal hus-
bandry, chemical characterization, adminis-
tration of test agent, treatment of controls,
evaluation of end points, and methods of
data analysis. Investigators from these
research groups were also available at the
meeting to give formal presentations of their
findings and to have informal discussions
with individual subpanels. Because of the
extreme rigor of this evaluation and the
extensive analyses of raw data performed by
the statistics subpanel, unpublished studies
were also included in this peer review.
The selected studies included a) treat-
ments with bisphenol A, diethylstilbestrol
(DES), ethinyl estradiol, nonylphenol,
octylphenol, genistein, methoxychlor,
17β–estradiol, and vinclozolin, or b) effects
of diet or intrauterine position. Exposure
periods included in utero, neonatal, pubertal,
adult, in utero through neonatal, in utero
through puberty, and in utero through adult.
Requested parameters included organ
weights (prostate, testis, epididymis, seminal
vesicle, preputial gland, uterus, and ovary),
perinatal measures (e.g., anogenital dis-
tance), pubertal measures (e.g., age at vaginal
opening, first estrus, preputial separation,
and testis descent), and other relevant factors
(e.g., daily sperm production, sperm count,
serum hormone levels, lymphocyte prolifera-
tion in response to anti-CD3, histopathol-
ogy, estrous cyclicity, receptor binding,
estrogen-receptor levels, gene expression, and
volume of sexually dimorphic nuclei of the
preoptic area of the hypothalamus). To con-
duct this evaluation within a reasonable time
frame, this review focused on reproductive
and developmental effects. The extensive lit-
erature on dioxin and dioxin-like compounds
was excluded because the U.S. EPA was ﬁnal-
izing its extensive and rigorous reevaluation
of dioxin risk. Phthalate esters were also
excluded because separate evaluations on
these compounds were being conducted by
the NTP Center for the Evaluation of Risks
to Human Reproduction. A future workshop
may focus on low-dose effects of dioxin-like
compounds.
The statistics subpanel analyzed the raw
data from 39 of the 49 submitted studies
over a 6-week period and provided results
from these analyses to the other subpanels 1
week before the peer-review meeting. These
analyses provide greater insight on the
experimental data than is typically apparent
in most peer-reviewed research articles; con-
sequently, the statisticians’ report was critical
for each of the subpanel reviews. 
Prior to the meeting, the Dose–Response
Modeling group provided theoretical
dose–response models based on mechanisms
of receptor-mediated processes, as well as
empirical dose–response models of endocrine-
related effects. Several important statistical
issues were identified by the subpanel and
are addressed in their report; these include
study sensitivity (power), adjustment for lit-
ter effects, pooling of control groups, exclu-
sion of statistical outliers, accounting for
body weight differences on organ weight
effects, appropriateness of the selected statis-
tical methodology, and data heterogeneity
across dose groups. All of these matters, plus
experimental design and conduct issues,
were considered by each of the subpanels in
their evaluations of the individual studies
during the peer review. The statisticians and
modelers participated in the other subpanel
reviews to ensure that their analyses and
models were appropriately used by the sub-
panels. A manuscript on the approach and
general ﬁndings of the statistics subpanel was
published recently (2). 
The panel evaluated data from the major
selected studies that support the presence or
absence of low-dose effects in laboratory ani-
mals and that would be relevant for human
health assessments. Hard copies of the publi-
cations or reports of the selected studies were
sent to each of the panel members 2 months
before the peer-review meeting. Low-dose
effects analyzed by the panel should be con-
sidered as effects occurring at no-observed-
effect levels (NOELs) because this review did
not distinguish adverse versus nonadverse
effects. However, the panel did compare,
when appropriate, its analyses to existing 
no-observed-adverse-effect levels (NOAELs)
or lowest-observed-adverse-effect levels
(LOAELs) reported by the U.S. EPA or oth-
ers. The panel was also asked to consider
biologic and mechanistic data that might
inﬂuence the plausibility of low-dose effects
and to identify study design issues or other
biologic factors that might account for dif-
ferences in study outcomes. Conclusions
from the panel on the existence of low-dose
effects and the shape of the dose–response
curve for endocrine-active substances in the
low-dose region were based on the totality of
available knowledge. 
This unique scientific peer review pro-
vided an extraordinarily rigorous, open,
transparent, and objective evaluation of the
scientific evidence showing the presence or
absence of low-dose effects of endocrine-
disrupting agents and an opportunity for
participation by all stakeholders who had
interest in this scientiﬁc review. The indepen-
dently prepared reports of the subpanels, as
well as information on the selected studies and
requested parameters, can be accessed at the
NTP web site (3). Alternatively, hard copies of
the ﬁnal report can be obtained by contacting
the U.S. EPA Ofﬁce of Prevention, Pesticides,
and Toxic Substances docket-42208A, (202)
260-7099. Highlights of the ﬁndings of the
subpanels are given below.
Peer-Review Subpanel
Findings
Bisphenol A. On the basis of the U.S. EPA
estimate that the LOAEL for oral exposure
to bisphenol A in rats is 50 mg/kg/day, the
subpanel used 5 mg/kg/day as a cutoff dose
for low-dose effects, regardless of the route
or duration of exposure or the age/life stage
at which exposure occurred. 
Several studies provide credible evidence
for low-dose effects of bisphenol A. These
include increased prostate weight in male
mice at 6 months of age and advanced
puberty in female mice after in utero expo-
sure to 2 or 20 µg/kg/day, and low-dose
effects on uterine growth and serum pro-
lactin levels that occurred in F344 rats but
not in Sprague-Dawley rats exposed to 0.5
mg/kg/day. The latter ﬁndings demonstrate
a clear difference in sensitivity to the estro-
genic effects of bisphenol A in these two
strains of rats. 
Several large studies in rats and mice,
including multigenerational studies in
Sprague-Dawley rats, found no evidence for
a low-dose effect of bisphenol A, despite the
considerable strength and statistical power
those studies represent. 
For those studies that included DES
exposure groups, those that showed an effect
with bisphenol A showed a similar low-dose
effect with DES (e.g., prostate and uterus
enlargement in mice); those that showed no
effect with bisphenol A also found no effect
with DES. 
Discrepancies in experimental outcome
among studies showing positive and negative
effects of bisphenol A may have been due to
different diets with differing background lev-
els of phytoestrogens, differences in strains of
animals used, differences in dosing regimen,
and differences in housing of animals (singly
vs. group). Although some studies attempted
to replicate previous ﬁndings, body weights
and prostate weights of controls differed
between these studies. Studies also differed
in the extent of analysis of dosing solutions.
The subpanel concluded that “there is
credible evidence that low doses of BPA
[bisphenol A] can cause effects on specific
end points. However, due to the inability of
other credible studies in several different
laboratories to observe low dose effects of
BPA, and the consistency of these negative
studies, the subpanel is not persuaded that a
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sively established as a general or repro-
ducible ﬁnding.”
Data are insufficient to establish the
shape of the dose–response curve for bisphe-
nol A in the low-dose region, and the mech-
anism and biologic relevance of reported
low-dose effects are unclear.
The subpanel identified areas for addi-
tional research that would clarify uncertain-
ties about low-dose effects of bisphenol A.
These areas include
• additional low-dose studies, including the
development and use of sensitive and easily
measured molecular end points, following
in utero as well as early neonatal exposure
to conclusively establish low-dose effects of
bisphenol A as a general, reproducible phe-
nomenon; 
• pharmacokinetic data in multiple species
and strains of animals to characterize fetal
uptake, metabolism, and elimination of
bisphenol A and its metabolites;
• mechanistic data on estrogen receptor
occupancy during critical periods of devel-
opment, effects of speciﬁc receptor antago-
nists, and responses in estrogen-receptor
knockout mice; 
• additional studies to ascertain the effects of
endogenous hormone levels as a function
of intrauterine position;
• studies to evaluate the effects of differing
levels of estrogenic components present in
various feeds;
• characterization of genetic and epigenetic
factors that affect responses to bisphenol A
and hormones in general—e.g., factors that
lead to strain and species differences in sen-
sitivity;
• mechanistic studies on the effects of
bisphenol A on regulation of transcrip-
tional activity from gestation through
adulthood.
Other environmental estrogens and
estradiol. The subpanel developed an opera-
tional deﬁnition for low-dose effects that was
based on the dose–response data for the
selected end points for each agent under
evaluation. Low-dose effects were considered
to be occurring when a nonmonotonic dose
response resulted in signiﬁcant effects below
the presumed NOEL expected by the tradi-
tional testing paradigm.
Low-dose effects were clearly demon-
strated for estradiol and several other
estrogenic compounds. The shape of the
dose–response curves for effects of estrogenic
compounds varies with the end point and the
dosing regimen. Theoretical models based on
mechanisms of receptor-mediated processes, as
well as empirical models of endocrine-related
effects, produced dose–response shapes that
were either low-dose linear, or threshold-
appearing, or nonmonotonic (e.g., U-shaped
or inverted U-shaped). Low-dose effects of
the estrogenic agents evaluated by the sub-
panel include the following:
• For estradiol (ovarian steroid with greatest
estrogenic activity), low-dose effects
include changes in serum prolactin,
luteinizing hormone, and follicle-stimulat-
ing hormone in ovariectomized rats at a
dose of approximately 3 µg/kg/day.
• DES, a nonsteroidal synthetic estrogen
that had been used to prevent spontaneous
abortions and to enhance cattle weight
gain, is a transplacental carcinogen in
humans. There is clear evidence of a low-
dose effect on prostate size after in utero
exposure of mice to DES at 0.02 µg/kg.
• For genistein (isoﬂavone derived from soy),
low-dose effects were observed in F1 off-
spring following dietary exposure (in utero
through puberty) to 25 ppm. These effects
include a decrease in the volume of sexually
dimorphic nuclei of the preoptic area (SDN-
POA) of the hypothalamus in male rats
(approaching femalelike volumes), changes
in mammary gland tissue in male rats, and
an increase in proliferation of splenic T-lym-
phocytes stimulated with anti-CD3.
• For methoxychlor (insecticide), classic
estrogenic activity occurs in F1 rats follow-
ing in utero and perinatal exposure to 5
mg/kg/day or higher doses. Low-dose
immune system effects occur in F1 off-
spring following dietary exposure (in utero
through puberty) to 10 ppm methoxychlor
(approximately equal to 1 mg/kg/day).
• For nonylphenol (industrial compound
identiﬁed in drinking water supplies), low-
dose effects in F1 rats following dietary
exposure (in utero through puberty) to 25
ppm include a decrease in SDN-POA in
males, an increase in relative thymus
weight, an increase in proliferation of
splenic T-lymphocytes stimulated with
anti-CD3, and a prolonged estrus in
females.
• For octylphenol (an intermediate for the
production of surfactants), there was no
evidence of low-dose effects in a ﬁve-dose
multigeneration study in rats.
Areas of future research include
• multiple dose studies and modeling of
dose–response relationships;
• need for replication of low-dose ﬁndings in
other studies or in other laboratories;
• determination of the toxicologic signifi-
cance of volume changes in SDN-POA in
male rats and the relationship between
estrogenic activity and stimulation of lym-
phocyte proliferation.
Androgens and antiandrogens. The sub-
panel’s review focused on low-dose effects of
vinclozolin, a fungicide that is an androgen
receptor antagonist. NOAELs for vinclozolin
were established from studies in rats; these
levels are 6 mg/kg/day for acute dietary
exposure and 1.2 mg/kg/day from chronic
dietary exposure. No studies have been con-
ducted on vinclozolin at doses below its
NOAEL. 
Exposure of pregnant rats to vinclozolin
at six doses ranging from 3.125 to 100
mg/kg/day results in reduced anogenital dis-
tance (femalelike), increased incidences of
areolas and nipple retention, and perma-
nently reduced ventral prostate weight in
male offspring. For these effects, the
dose–response curves appeared linear to the
lowest dose tested. Reproductive tract mal-
formations and reduced ejaculated sperm
numbers were observed only at the two
highest doses. Thus, dose–response relation-
ships are not equivalent among end points
affected by exposure to vinclozolin. 
Antiandrogens act as androgen receptor
antagonists, inhibitors of 5α–reductase activ-
ity, and/or inhibitors of steroidogenesis. In
addition to vinclozolin, other agents (or their
metabolites) that have been identified as
antiandrogens include p,p´-dichlorodiphenyl-
trichloroethane (insecticide), ﬂutamide, and
Casodex (pharmaceuticals developed to treat
prostate cancer), ﬁnasteride (pharmaceutical
developed to treat benign prostate hyperpla-
sia), methoxychlor (pesticide), procymidone
(fungicide), linuron (herbicide), ketoconazole
(fungicide), and certain phthalate esters (plas-
ticizers). For finasteride, which acts as a
5α–reductase inhibitor, the dose response for
reduction in anogenital distance (linear) was
different than that for increased hypospadias
(threshold-appearing).
No data are available on low-dose effects
of environmental chemicals that act as
androgen mimics. 
Future research needs include the
following: 
• further testing of the hypothesis that the
dose response for antiandrogens is linear to
the NOAEL/LOAEL; 
• development of mechanism-based assays
for the detection of androgen mimics;
• development and use of molecular and bio-
chemical markers as sensitive indicators of
low-dose effects of androgenic and antian-
drogenic agents; 
• characterization of dose–response relation-
ships for androgenic and antiandrogenic
agents in different species and in multiple
strains; 
• development of dosimetry/mechanistic
models for exposures occurring during in
utero and early neonatal development. 
Biological factors and study design.
Several factors may account for discrepant
findings on low-dose effects of particular
endocrine-active agents. These factors include
• intrauterine position, which (although not
essential for the detection of low-dose
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ability in response because differences in
fetal exposure to endogenous hormones
may influence responses associated with
exposure to endocrine-disrupting chemicals; 
• strain and substrain differences in response,
which could occur because of genetic dif-
ferences or selective breeding to maintain
high rates of fecundity and growth;
• diet with varying background levels of phy-
toestrogens and differences in caloric
intake, which might inﬂuence reproductive
parameters;
• differences in caging (e.g., stainless steel,
polycarbonate), bedding material, or hous-
ing (group versus individual), which could
inﬂuence study outcomes; 
• seasonal variation, which has been reported
to affect sex ratios in rodents.
Comments on the multigeneration test.
The traditional multigeneration reproduc-
tion study protocol includes exposure of
animals through most critical windows of
sexual differentiation in the F1 generation
and an assessment of the F2 generation
through postnatal day 21. This protocol
provides substantial information on repro-
ductive effects, but limited information on
developmental effects. Frequently, litter size
is reduced on postnatal day 4 (usually to
four males and four females), and litter size
is further reduced at weaning (postnatal day
21), so that only one animal/sex/litter is
held until adulthood. The reduction in
number of treated animals evaluated may
provide inadequate power to detect low-
incidence responses (e.g., reproductive tract
malformations). Further, a number of sensi-
tive or subtle endocrine-related end points
are not routinely evaluated, and evaluations
of F2 pups on or around postnatal day 21
may not reveal effects on reproductive tract
organs that are not yet fully developed. This
concern is underscored by the fact that cer-
tain endocrine-active chemicals were nega-
tive in standard multigeneration and
prenatal studies. 
Additional design factors for future stud-
ies include the following: 
• Because of clear species and strain differ-
ences in sensitivity, animal-model selection
should be based on responsiveness to
endocrine-active agents of concern (i.e.,
responsive to positive controls), not on
convenience and familiarity.
• Pharmacokinetic data need to be routinely
generated, using appropriately sensitive
methods, to characterize the dosimetry of
the test chemical or its metabolites in tar-
get tissues.
• Caution is needed in implementing
experimental designs to reduce animal vari-
ability (e.g., controlled feeding, individual
housing), because factors such as body
weight and stress can influence reproduc-
tive end points. 
• The biologic/toxicologic relevance of
specific end points affected by endocrine-
active agents would beneﬁt from measuring
functional parameters or collecting mecha-
nistic data on related biomarkers of effect. 
• The long-term health consequences of
early changes induced by endocrine-active
agents, e.g., prostate enlargement or accel-
erated uterine development, need to be
determined.
• Windows of susceptibility to endocrine-
disrupting chemicals need to be identiﬁed
from mechanistic data and empirical tests
need to include exposures at those times.
Overall Conclusions
Low-dose effects, as deﬁned for this review,
were demonstrated in laboratory animals
exposed to certain endocrine-active agents.
The effects are dependent on the compound
studied and the end point measured. In
some cases where low-dose effects have been
reported, the findings have not been repli-
cated. The toxicologic signiﬁcance of many
of these effects has not been determined.
The shape of the dose–response curves
for these effects varies with the end point and
dosing regimen, and may be low-dose linear,
threshold-appearing, or nonmonotonic.
The traditional multigeneration reproduc-
tion study protocol has not revealed major
reproductive or developmental effects in labo-
ratory animals exposed to endocrine-active
agents at doses approaching their NOAELs
set by the standard testing paradigm.
However, few multigenerational studies have
been conducted over expanded dose ranges,
and end points such as cancer of reproductive
organs or neurobehavioral effects are generally
not evaluated in multigenerational studies.
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Subpanels.
Bisphenol A
George Stancel (Chair)  University of Texas at Houston
Gail Prins (Rapporteur)  University of Illinois at Chicago
Ralph Cooper U.S. Environmental Protection Agency
Warren Foster  Health Canada
Jun Kanno  National Institute of Health Sciences – Japan
John Faust  California Environmental Protection Agency 
Other Environmental Estrogens and Estradiol
Michael Gallo (Chair)  UMDNJ-Robert Wood Johnson Medical School
Kenneth Reuhl (Rapporteur)  Rutgers University
Mari Golub  California Environmental Protection Agency
Claude Hughes UCLA School of Medicine
Richard Lyttle  Wyeth-Ayerst Research
Lynne McGrath  Schering-Plough Research Institute
Patricia Whitten  Emory University
Androgens and Antiandrogens
Shuk-Mei Ho (Chair)  University of Massachusetts Medical School
Terry Brown (Rapporteur)  Johns Hopkins University School of Public Health
George Daston  The Procter & Gamble Company
Mitch Eddy  National Institute of Environmental Health Sciences
Lorenz Rhomberg  Gradient Corporation
Elizabeth Wilson  University of North Carolina at Chapel Hill
Biological Factors and Study Design
John Moore (Chair)  Sciences International, Inc.
Julian Leakey (Rapporteur)  National Center for Toxicological Research
Sue Barlow  Consultant
Paul Foster  Chemical Industry Institute of Toxicology
Robert Luebke  U.S. Environmental Protection Agency
Robert Maronpot  National Institute of Environmental Health Sciences
Cory Teuscher  University of Illinois at Urbana-Champaign
Statistics and Dose–Response Modeling
Joseph Haseman (Co-chair, Statistics)  National Institute of Environmental Health Sciences
John Bailer  Miami University of Ohio
Ralph Kodell  National Center for Toxicological Research
Richard Morris  Analytical Sciences, Inc.
Kenneth Portier  University of Florida
Michael Kohn (Co-chair, Modeling)  National Institute of Environmental Health Sciences
Hugh Barton  U.S. Environmental Protection Agency
Jim Cogliano  U.S. Environmental Protection Agency
Rory Connolly  Chemical Industry Institute of Toxicology
Robert Delongchamp  National Center for Toxicological ResearchThe panel recommended additional
research to replicate previously reported key
low-dose ﬁndings, to characterize target tis-
sue dosimetry during critical periods of
development, to identify sensitive molecular
markers that would be useful in understand-
ing mechanistic events associated with
low-dose effects, and to determine the long-
term health consequences of low-dose effects
of endocrine-active agents.
The findings of the panel indicate that
the current testing paradigm used for assess-
ments of reproductive and developmental
toxicity should be revisited to see if changes
are needed regarding dose selection, animal
model selection, age when animals are eval-
uated, and the end points being measured
following exposure to endocrine-active
agents. 
REFERENCES AND NOTES
1. U.S. EPA. Health Effects Test Guidelines OPPTS 870.3800
Reproduction and Fertility Effects. EPA 712-C-98-208.
Washington, DC:U.S. Environmental Protection Agency,
1998.
2. Haseman JK, Bailer AJ, Kodell RL, Morris R, Portier K.
Statistical issues in the analysis of low-dose endocrine
disruptor data. Toxicol Sci 61:201–210 (2001).
3. National Toxicology Program homepage. Research
Triangle Park, NC:National Institute of Environmental
Health Sciences. Available: http://ntp.niehs.nih.gov/ [cited
1 August 2001].
Workshop Summary • Endocrine disruptors low-dose peer review
Environmental Health Perspectives • VOLUME 110 | NUMBER 4 | April 2002 431